From the Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia.
Infectious Diseases Group, Murdoch Children's Research Institute, Parkville, Victoria, Australia.
Pediatr Infect Dis J. 2021 Nov 1;40(11):1037-1045. doi: 10.1097/INF.0000000000003237.
There is no consensus on managing common adverse reactions to Bacille Calmette-Guérin (BCG) vaccination. We systematically reviewed the management of BCG-associated regional lymphadenitis and injection site abscess in immunocompetent individuals.
Searches of Medline, Embase and PubMed were done until November 2020. Randomized controlled trials (RCTs) and cohort studies that compared management strategies for complications of intradermal BCG vaccination were included.
Of 1338 individual articles, 15 met inclusion criteria. Six RCTs, 4 prospective and 4 retrospective cohort studies compared management in 1022 children with BCG-associated lymphadenitis. For nonsuppurative lymphadenitis, no antimicrobial was found to significantly impact on time to resolution or prevention of suppuration. For suppurative lymphadenitis, there was some evidence that needle aspiration shortens time to resolution and prevents sinus tract formation. Surgical excision (mainly offered for persistent suppurative lymphadenitis) generally had favorable outcome. Two cohort studies (including 1 aforementioned) compared management strategies in up to 36 children with BCG injection site abscess; one showed no difference in outcome in children treated with antibiotics and the other reported complete resolution without treatment.
Evidence does not support a role for antimicrobial therapy in the management of localized reactions to BCG vaccination in immunocompetent children. Needle aspiration may shorten the recovery period for BCG-associated suppurative lymphadenitis. BCG injection site abscess usually heals without treatment. However, studies are limited and cases are not well defined. Growing research into novel BCG applications provides opportunities to investigate optimal management strategies for adverse reactions in a prospective manner using active safety surveillance.
对于卡介苗(BCG)接种的常见不良反应的处理尚无共识。我们系统地回顾了免疫功能正常个体中与 BCG 相关的区域性淋巴结炎和注射部位脓肿的处理方法。
检索了 Medline、Embase 和 PubMed,检索时间截至 2020 年 11 月。纳入了比较皮内 BCG 疫苗接种并发症管理策略的随机对照试验(RCT)和队列研究。
在 1338 篇单独的文章中,有 15 篇符合纳入标准。6 项 RCT、4 项前瞻性和 4 项回顾性队列研究比较了 1022 例 BCG 相关淋巴结炎患儿的管理方法。对于非化脓性淋巴结炎,没有发现任何抗菌药物能显著影响其消退时间或化脓的预防。对于化脓性淋巴结炎,有一些证据表明,针吸可以缩短消退时间并预防窦道形成。手术切除(主要用于治疗持续性化脓性淋巴结炎)通常具有良好的效果。两项队列研究(包括上述一项)比较了多达 36 例 BCG 注射部位脓肿患儿的管理策略;一项研究表明,接受抗生素治疗的患儿结局无差异,另一项研究则报告无需治疗即可完全消退。
证据不支持在免疫功能正常的儿童中使用抗菌药物治疗 BCG 疫苗接种后局部反应。针吸可能缩短与 BCG 相关的化脓性淋巴结炎的恢复时间。BCG 注射部位脓肿通常无需治疗即可愈合。然而,研究有限,病例也未明确界定。针对新型 BCG 应用的研究不断增加,为前瞻性地使用主动安全性监测研究不良反应的最佳管理策略提供了机会。